Osseo Imaging v. Carestream Dental: Dental Imaging Patent Dispute Ends in Mutual Dismissal

Case Overview

The Parties

Patents at Issue

This case involved two U.S. patents covering dental and orthopedic densitometry modeling technology:

• • U.S. Patent No. 6,381,301 B1 — An earlier-generation patent covering core methods and systems in dental and orthopedic densitometry modeling.
• • U.S. Patent No. 8,498,374 B2 — A related patent extending protection into more refined densitometry modeling techniques.

Litigation Timeline & Procedural History

Timeline

Osseo Imaging filed its complaint on **July 14, 2023**, before the U.S. District Court for the Northern District of Georgia. The case, docketed as **1:23-cv-03116**, ran for **585 days**—approximately 19 months—before closing on **February 18, 2025**.

Procedural History

The case concluded via **mutual stipulated dismissal with prejudice** on February 18, 2025, under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Both parties agreed to bear their own attorneys’ fees and costs, and the action was immediately terminated. No publicly disclosed trial verdict, summary judgment ruling, or claim construction order appears in the provided case data.

The Verdict & Legal Analysis

Outcome

The case concluded via mutual stipulated dismissal with prejudice. No damages award was disclosed, and no injunctive relief was granted. The specific financial terms of any underlying settlement agreement, if one exists separate from the public stipulation, were not disclosed in the case record.

Verdict Cause Analysis

The bilateral nature of the dismissal with prejudice—and the mutual release of all claims that “could have been raised”—is a hallmark of a negotiated resolution. Carestream’s counterclaims, likely including invalidity challenges, were also dismissed with prejudice, a concession that patent holders typically extract as a condition of settlement.

Legal Significance

The “could have raised” language in the stipulation is significant, creating broad preclusive effect and foreclosing future litigation on related theories under claim preclusion principles. For U.S. Patent Nos. 6,381,301 B1 and 8,498,374 B2, expiration timing and remaining commercial enforceability would similarly factor into the litigation economics calculus for other parties.

Strategic Takeaways

For Patent Holders: Osseo’s assertion of two related densitometry patents created layered infringement exposure for Carestream—a strategy that increases settlement leverage. Maintaining a coordinated patent family on core technology enables this approach.

For Accused Infringers: Carestream’s decision to engage Thompson Hine’s full litigation team—including counterclaim preparation—likely strengthened its bargaining position. Credible invalidity counterclaims are essential negotiating tools in patent disputes.

For R&D Teams: Engineers developing dental imaging software with density modeling capabilities should conduct Freedom to Operate (FTO) analyses against both patents before product launch. Even post-litigation patents remain enforceable against third parties not party to this stipulation.